
Evaluating Class-Level and Agent-Level Differences Among CELMoDs in Relapsed/Refractory Multiple Myeloma
In the final round of the Hot Topics Debate, Teams Catalyst and Compass discuss whether CELMoDs should be considered a single therapeutic class or whether clinically meaningful differences exist among individual agents.
Episodes in this series

In the final round of the Hot Topics Debate, Teams Catalyst and Compass discuss whether CELMoDs should be considered a single therapeutic class or whether clinically meaningful differences exist among individual agents. Team Catalyst emphasizes the shared cereblon-mediated mechanism of action, broadly consistent efficacy across different settings, and similar toxicity profiles, suggesting that treatment selection may depend largely on the combination partner and treatment backbone. Team Compass argues that differences in potency, patient populations, prior treatment exposure, and study designs may influence clinical decision-making. Faculty compare iberdomide and mezigdomide with earlier immunomodulatory drugs, discussing whether activity may be retained when switching between agents after disease progression. The panel acknowledges that direct evidence establishing the efficacy of one CELMoD after another remains limited. However, some faculty suggest that differences in potency and disease sensitivity could support sequential use in selected patients. The discussion highlights the need for further evidence to clarify agent-specific activity and inform individualized treatment selection in relapsed/refractory multiple myeloma.
Related to this article








